These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34409538)

  • 1. Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.
    Doorley JD; Greenberg J; Bakhshaie J; Fishbein NS; Vranceanu AM
    J Neurooncol; 2021 Sep; 154(2):257-263. PubMed ID: 34409538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
    Fishbein NS; Vranceanu AM; Mace RA
    J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis.
    Mace RA; Doorley J; Bakhshaie J; Cohen JE; Vranceanu AM
    J Neurooncol; 2021 Nov; 155(2):125-132. PubMed ID: 34570301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence and Severity of Suicidal Ideation in Adults With Neurofibromatosis Participating in a Mind-Body RCT.
    Lester EG; Wang KE; Blakeley JO; Vranceanu AM
    Cogn Behav Neurol; 2023 Mar; 36(1):19-27. PubMed ID: 36651958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
    Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
    Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.
    Vranceanu AM; Riklin E; Merker VL; Macklin EA; Park ER; Plotkin SR
    Neurology; 2016 Aug; 87(8):806-14. PubMed ID: 27449066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
    Vranceanu AM; Merker VL; Plotkin SR; Park ER
    J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of a virtual mind-body program on symptoms of depression and anxiety among international English-speaking adults with neurofibromatosis.
    McDermott K; Bakhshaie J; Brewer J; Vranceanu AM
    Am J Med Genet A; 2024 Jun; 194(6):e63543. PubMed ID: 38318960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1.
    Kongkriangkai AM; King C; Martin LJ; Wakefield E; Prada CE; Kelly-Mancuso G; Schorry EK
    Am J Med Genet A; 2019 Apr; 179(4):602-607. PubMed ID: 30737893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
    Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
    BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
    Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM
    J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
    Vranceanu AM; Merker VL; Park E; Plotkin SR
    J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.
    Wang DL; Smith KB; Esparza S; Leigh FA; Muzikansky A; Park ER; Plotkin SR
    Genet Med; 2012 Dec; 14(12):977-82. PubMed ID: 22878510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial.
    Reichman M; Riklin E; Macklin E; Vranceanu AM
    Contemp Clin Trials; 2020 Aug; 95():106078. PubMed ID: 32634485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
    Talaei-Khoei M; Riklin E; Merker VL; Sheridan MR; Jordan JT; Plotkin SR; Vranceanu AM
    J Neurooncol; 2017 Jan; 131(2):413-419. PubMed ID: 27900643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resiliency outcomes after participation in an asynchronous web-based platform for adults with neurofibromatosis: The NF-Web study.
    Wang KE; Vranceanu AM; Lester EG
    PLoS One; 2023; 18(12):e0295546. PubMed ID: 38127915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
    Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
    Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.